-
Human Capital Report 2023
A report summarizing our approach to human capital and related KPIs.
-
New Innovation Page Launch
-
Eisai’s Efforts on Global Health
-
November 22, 2023
-
November 20, 2023
LEQEMBI® Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023
-
November 16, 2023
-
October 26, 2023
-
October 25, 2023
LEQEMBI® (LECANEMAB-IRMB) NAMED ONE OF TIME’S BEST INVENTIONS OF 2023
-
November 8, 2023
-
November 7, 2023
IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2024”
-
November 6, 2023
Sustainability "Lymphatic Filariasis Elimination Activities in Myanmar ー Message from a DEC Manager"
-
October 27, 2023
-
October 26, 2023
-
October 13, 2023
-
March 9, 2023
Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties
-
February 17, 2023
EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA
-
July 15, 2022
Notification Regarding U.S. Research and Development Subsidiary
-
April 1, 2022
Sustainability
30 countries 2.16 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of October 2023)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries